Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities

被引:0
|
作者
Awan, Aiman B. [1 ]
Osman, Maryiam Jama Ali [1 ,2 ]
Khan, Omar M. [1 ]
机构
[1] Hamad Bin Khalifa Univ, Coll Hlth & Life Sci, POB 34110, Doha, Qatar
[2] Sidra Med, Res Branch, POB 34110, Doha, Qatar
关键词
ubiquitination; cell cycle; E3; ligases; oncogenes; tumor suppressor; PROTACs; cancer; immune evasion; SMALL-MOLECULE INHIBITORS; TUMOR-SUPPRESSOR; E3; LIGASE; ACTIVATING ENZYME; PEVONEDISTAT TAK-924/MLN4924; PROTEASOMAL DEGRADATION; MEDIATED DEGRADATION; PROTEIN-DEGRADATION; NEGATIVE REGULATION; MASTER REGULATOR;
D O I
10.3390/cells14020069
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Ubiquitination is cells' second most abundant posttranslational protein modification after phosphorylation. The ubiquitin-proteasome system (UPS) is critical in maintaining essential life processes such as cell cycle control, DNA damage repair, and apoptosis. Mutations in ubiquitination pathway genes are strongly linked to the development and spread of multiple cancers since several of the UPS family members possess oncogenic or tumor suppressor activities. This comprehensive review delves into understanding the ubiquitin code, shedding light on its role in cancer cell biology and immune evasion. Furthermore, we highlighted recent advances in the field for targeting the UPS pathway members for effective therapeutic intervention against human cancers. We also discussed the recent update on small-molecule inhibitors and PROTACs and their progress in preclinical and clinical trials.
引用
收藏
页数:35
相关论文
共 50 条
  • [41] Mechanisms of immune evasion in breast cancer
    Joshua P. Bates
    Roshanak Derakhshandeh
    Laundette Jones
    Tonya J. Webb
    BMC Cancer, 18
  • [42] The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches
    Pandya, Pankita H.
    Murray, Mary E.
    Pollok, Karen E.
    Renbarger, Jamie L.
    JOURNAL OF IMMUNOLOGY RESEARCH, 2016, 2016
  • [43] Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer
    Trackman, Philip C.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (08) : 935 - 945
  • [44] Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities
    Canale, Matteo
    Casadei-Gardini, Andrea
    Ulivi, Paola
    Arechederra, Maria
    Berasain, Carmen
    Lollini, Pier-Luigi
    Fernandez-Barrena, Maite G.
    Avila, Matias A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 21
  • [45] Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer
    Parcesepe, Pietro
    Giordano, Guido
    Laudanna, Carmelo
    Febbraro, Antonio
    Pancione, Massimo
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2016, 2016
  • [46] RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
    Zhang, Yangyang
    Zeng, Lingxiu
    Wang, Meng
    Yang, Zhenwei
    Zhang, Hailin
    Gao, Liping
    Zhang, Ranran
    Liu, Jialong
    Shan, Wenqing
    Chang, Ying
    Liu, Lan
    Zhao, Qiu
    Li, Yong
    Liu, Jing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
  • [47] Deubiquitinating enzymes: potential regulators of the tumor microenvironment and implications for immune evasion
    Hsu, Sheng-Kai
    Chou, Chon-Kit
    Lin, I-Ling
    Chang, Wen-Tsan
    Kuo, I-Ying
    Chiu, Chien-Chih
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [48] The role of Fusobacteria in oral cancer and immune evasion
    Harrandah, Amani M.
    CURRENT OPINION IN ONCOLOGY, 2023, 35 (02) : 125 - 131
  • [49] Strategies for Overcoming Immune Evasion in Bladder Cancer
    Shin, Juhyun
    Park, Jeong Won
    Kim, Seon Young
    Lee, Jun Ho
    Choi, Wahn Soo
    Kim, Hyuk Soon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [50] Immune evasion: a requirement for breast cancer metastasis?
    Bidwell, Bradley N.
    Parker, Belinda S.
    Anderson, Robin L.
    CLINICAL & EXPERIMENTAL METASTASIS, 2007, 24 (04) : 293 - 294